Business Wire

CRESTBRIDGE

25.7.2022 16:48:05 CEST | Business Wire | Press release

Share
Crestbridge Appoints New Luxembourg Country Head, as the Business Advances Its Leading Position Locally and Internationally

Crestbridge, the agile alternative for private equity and real estate administration solutions, today announced the appointment of Anne Catherine Grave as Country Head of Luxembourg.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005497/en/

Based in Luxembourg, Anne Catherine will be responsible for leading the business in the region and building on its reputation as a leading service provider for fund managers.

Since establishing a presence in Luxembourg 11 years ago, Crestbridge has continued its commitment to quality, evolving its service proposition in line with the jurisdiction’s own exponential growth. This is testament to Crestbridge’s popularity amongst fund managers, driven by the firm's expertise in management company services, private equity, real estate, private debt and venture capital.

Anne Catherine’s appointment adds further weight to Crestbridge’s highly experienced Luxembourg team, who provides global, comprehensive support to fund managers. This includes managing the administrative, accounting, reporting, residency and governance needs of a broad range of fund structures throughout their lifecycles.

Prior to joining Crestbridge, Anne Catherine was the Partner in charge of Corporate Secretarial Services in Deloitte in Luxembourg. She has over 20 years' experience in Private Equity and Real Estate sectors.

Anne Catherine gained her extensive experience as part of the Management/Executive Committees of Arendt Services in Luxembourg, as well as in her position as Executive Director of Bedell (which became Ocorian), a Luxembourg Trust & Fund business of a Jersey Group. In both positions, she served as board members of various regulated and non-regulated clients’ entities. Anne Catherine’s area of activities included the compliance, corporate, governance, tax, internal control and risk management functions. She started her career as tax advisor in Ernst & Young in Luxembourg and New York, before transitioning into a Senior Tax Lawyer position at a Luxembourg Law Firm, Arendt.

Anne Catherine holds masters’ degrees in economics and in International & European law, a post-graduate diplomas in Political Sciences as well as in International Business Law. She is also qualified as a Certified International Control Specialist and has a qualification in risk management. She was a Chartered Accountant in Luxembourg and a qualified attorney in France and Luxembourg. Anne Catherine was the Chair of the ILA Company Secretary and Governance Officer Committee for 4 years. She remains an active member of such committee and is a speaker for the ILA Company Secretary and Governance Officer Committee certification.

Michael Johnson, Group Head of Institutional Services, Crestbridge, said:

“I'm delighted to welcome Anne Catherine to the team and am delighted that Crestbridge continues to be a business where top, global talent comes to work and thrive. Anne Catherine will be leading some of the best talent available in the region, people who are focused on delivering exceptional service and innovative solutions to our global client base. Anne Catherine offers the team not only considerable technical expertise but vast knowledge, having worked with some of the biggest names in the industry. I look forward to her playing a vital role in leading and driving forward our Luxembourg and international business.”

-ENDS-

Notes to editors

  • We are a leading global administration, management & corporate governance solutions business.
  • We provide a broad range of outsourced fiduciary, administrative, accounting, and compliance services globally – our expertise spans services, asset classes, and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers, and ultra-high net worth families.
  • Crestbridge employs over 500+ people and has nine international offices: Bahrain, Cayman, Ireland, Jersey, London, Luxembourg, New Jersey, New York, and Southampton.
  • We are regulated in our locations (see here for more details)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye